Grufity logo
Grufity logo

Latest Versant Venture Management, LLC Stock Portfolio

$141Million | No. of Holdings #8

Versant Venture Management, LLC Performance

2026 Q1-9.99%
YTD-9.99%
2025-28.54%

About Versant Venture Management, LLC and 13F Hedge Fund Stock Holdings

On 2026-05-05, the fund reported it's updated stock portfolio. In the 13F Holdings report, Versant Venture Management, LLC reported an equity portfolio of $141.4 Millions as of 31 Mar, 2026. <br><br> The top stock holdings of Versant Venture Management, LLC are GLUE, IPSC, . The fund has invested 37% of it's portfolio in MONTE ROSA THERAPEUTICS, INC. and 19.4% of portfolio in CENTURY THERAPEUTICS, INC. <br><br> They significantly reduced their stock positions in MONTE ROSA THERAPEUTICS, INC. (GLUE). Versant Venture Management, LLC opened new stock positions in CENTURY THERAPEUTICS, INC. (IPSC).
Versant Venture Management, LLC Equity Portfolio Value
Last Reported on: 05 May, 2026
$141Million
  as of May 05, 2026

Versant Venture Management, LLC Annual Return Estimates Vs S&P 500

Our best estimate is that Versant Venture Management, LLC made a return of -9.99% in the last quarter. In trailing 12 months, it's portfolio return was -7.69%.
  • Performance
  • S&P 500

New Buys

Ticker$ Bought
century therapeutics, inc.27,495,400
New stocks bought by Versant Venture Management, LLC

Additions

No additions were made to existing positions by Versant Venture Management, LLC

Reductions

Ticker% Reduced
monte rosa therapeutics, inc.-27.42
Versant Venture Management, LLC reduced stake in above stock

Sold off

None of the stocks were completely sold off by Versant Venture Management, LLC

Sector Distribution

Versant Venture Management, LLC has about 76.9% of it's holdings in Healthcare sector.

  • Healthcare
  • Others
Sector%
Healthcare76.9
Others23.1

Market Cap. Distribution

Versant Venture Management, LLC has about 0% of it's portfolio invested in the large-cap and mega-cap stocks.

  • SMALL-CAP
  • UNALLOCATED
  • MICRO-CAP
  • MID-CAP
Category%
SMALL-CAP52.2
UNALLOCATED23.1
MICRO-CAP19.4
MID-CAP5

Stocks belong to which Index?

About 71.6% of the stocks held by Versant Venture Management, LLC either belong to S&P 500 or RUSSELL 2000 index.

  • RUSSELL 2000
  • Others
Index%
RUSSELL 200071.6
Others28.4
Top 5 Winners (%)%
contineum therapeutics, inc.
14.3 %
GLUE
monte rosa therapeutics, inc.
4.2 %
Top 5 Winners ($)$
GLUE
monte rosa therapeutics, inc.
2.9 M
contineum therapeutics, inc.
0.9 M
Top 5 Losers (%)%
TPST
tempest therapeutics, inc.
-42.9 %
lenz therapeutics, inc.
-42.8 %
SKYE
skye bioscience, inc.
-18.0 %
CRSP
crispr therapeutics ag
-9.3 %
AVTE
jade biosciences, inc.
-8.9 %
Top 5 Losers ($)$
lenz therapeutics, inc.
-18.2 M
AVTE
jade biosciences, inc.
-2.1 M
CRSP
crispr therapeutics ag
-0.7 M
TPST
tempest therapeutics, inc.
-0.3 M
SKYE
skye bioscience, inc.
-0.3 M

Versant Venture Management, LLC Holdings Map

This heatmap illustrates the top 50 positions within the fund's portfolio.

Current Stock Holdings of Versant Venture Management, LLC

Versant Venture Management, LLC has 8 stocks in it's portfolio. proved to be the most loss making stock for the portfolio. GLUE was the most profitable stock for Versant Venture Management, LLC last quarter.

$141.41MTotal Value
8.00Positions
05 May, 2026Last Reported
Current holdings of Current Stock Holdings of Versant Venture Management, LLC, last reported on 05 May, 2026. Select a row with a linked ticker to view its historical trend.
ExpandHoldingsorted ascending% PortfolioShares Held$ Value% Change
SKYE
Skye Bioscience, Inc.

Skye Bioscience, Inc.

SKYE
Versant Venture Management, LLC's holding in Skye Bioscience, Inc. over time
0.87%2,007,700
$1.23M
0.87%
unchanged 0 percentunchanged
Common Stock
Lenz Therapeutics, Inc.

Lenz Therapeutics, Inc.

Versant Venture Management, LLC's holding in Lenz Therapeutics, Inc. over time
17.19%2,656,890
$24.31M
17.19%
unchanged 0 percentunchanged
Common Stock
Contineum Therapeutics, Inc.

Contineum Therapeutics, Inc.

Versant Venture Management, LLC's holding in Contineum Therapeutics, Inc. over time
5.01%542,628
$7.09M
5.01%
unchanged 0 percentunchanged